Routine screening at 30 for three genetic conditions that predispose to cancer and cardiovascular disease could save health services money, according to a recently publish
In another look back to ASCO 2023, pharmaphorum editor-in-chief Jonah Comstock spoke with Janssen's Martin Vogel and Edmond Chan, EMEA leads for oncology and haematology, respectively.
The development of Kura Oncology’s menin inhibitor ziftomenib for acute myeloid leukaemia has been held back by safety concerns in the past, but new data suggests the prog
At ASCO 2023 last week in Chicago, editor-in-chief Jonah Comstock caught up with Dr Corina Dutcus, SVP clinical development at Eisai US, to talk about the CLEAR trial, one of Eisai’s major
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.